Perspective Therapeutics
CATXPerspective Therapeutics is a radiopharmaceutical company specializing in the development of targeted alpha therapies (TAT) for various cancer types.
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Valuation & ratios
Competitors
By market cap
By net margin
Profile
Perspective Therapeutics is a radiopharmaceutical company specializing in the development of targeted alpha therapies (TAT) for various cancer types. The company utilizes its proprietary Lead-212 (212Pb) isotope technology to deliver precise radiation to cancer cells while employing complementary Lead-203 (203Pb) imaging diagnostics for a personalized theranostic approach. Their core value proposition lies in a scalable manufacturing platform and a pipeline of precision oncology treatments designed to improve efficacy and minimize toxicity compared to traditional radiation therapies.
Perspective is a pioneer in Lead-212 based alpha therapies, positioning itself as a next-generation alternative to established beta-emitting radiopharmaceutical providers.
Questions, answered.
- What is Perspective Therapeutics's market cap?
- Perspective Therapeutics (CATX) has a market capitalization of $321.6M and trades on AMEX.
- Who are Perspective Therapeutics's competitors?
- Perspective Therapeutics's key competitors include Actinium Pharmaceuticals, Eli Lilly, PLUS THERAPEUTICS, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Perspective Therapeutics partner with?
- Perspective Therapeutics's notable partners include Lantheus Holdings, Inc., Bristol Myers Squibb, Comecer SpA, and others.
- What subsidiaries does Perspective Therapeutics have?
- Perspective Therapeutics's subsidiaries include Isoray Medical, Inc., Viewpoint Molecular Targeting, Inc..
- Where is Perspective Therapeutics headquartered?
- Perspective Therapeutics is headquartered in United States of America and employs approximately 119 people. It has been publicly traded since 2003.